NASDAQ:HRMY Harmony Biosciences Q3 2026 Earnings Date & Estimates $36.83 +0.70 (+1.94%) Closing price 04:00 PM EasternExtended Trading$36.90 +0.07 (+0.19%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Harmony Biosciences is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Harmony Biosciences in Q3 2026Harmony Biosciences is expected to post earnings of $1.11 per share on revenue of $274.04 million. In the same quarter a year earlier Harmony Biosciences reported $0.87 per share on revenue of $239.46 million. Harmony Biosciences last reported on August 4, 2026, posting $1.28 per share and beating the $0.9560 consensus estimate. Harmony Biosciences has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS$1.11Expected Revenue$274.04 millionPrior-Year EPS$0.87Prior-Year Revenue$239.46 millionExpected EPS Growth+27.6%Expected Revenue Growth+14.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$1.28 (Beat by +$0.3240)Last Quarter Revenue$261.28 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Harmony Biosciences Q3 2026 Earnings FAQ When does Harmony Biosciences report Q3 2026 earnings? Harmony Biosciences (NASDAQ:HRMY) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Harmony Biosciences' Q3 2026 earnings call? Harmony Biosciences' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Harmony Biosciences? Analysts expect Harmony Biosciences to post earnings of $1.11 per share for Q3 2026. How much revenue is Harmony Biosciences expected to report? The consensus revenue estimate for Harmony Biosciences is $274.04 million for Q3 2026. Harmony Biosciences Earnings HeadlinesHarmony Biosciences drops amid court hearing on Wakix patentOctober 22, 2026 | msn.comRevisiting Former Stock Picks Marriott, Logitech, Harmony BiosciencesOctober 21, 2026 | barrons.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 26 at 1:00 AM | Crypto 101 Media (Ad)Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over ItOctober 21, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Zai Lab (ZLAB)October 20, 2026 | theglobeandmail.comHarmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026October 20, 2026 | globenewswire.comSee More Harmony Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Harmony Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harmony Biosciences and other key companies, straight to your email. Email Address About Harmony BiosciencesHarmony Biosciences (NASDAQ:HRMY) is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited. Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy. It is also approved for the treatment of excessive daytime sleepiness in adults with idiopathic hypersomnia. Founded in 2017, Harmony Biosciences primarily serves the U.S. market and continues to evaluate additional applications and development opportunities for therapies addressing neurological and sleep-related conditions. The company is led by Jeffrey M. Day, who serves as president and chief executive officer.View Harmony Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
